0001493152-18-002597.txt : 20180226
0001493152-18-002597.hdr.sgml : 20180226
20180226162350
ACCESSION NUMBER: 0001493152-18-002597
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180223
FILED AS OF DATE: 20180226
DATE AS OF CHANGE: 20180226
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Karkus Ted William
CENTRAL INDEX KEY: 0001457896
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-21617
FILM NUMBER: 18640845
MAIL ADDRESS:
STREET 1: 188 HEWLETT NECK ROAD
CITY: WOODMERE
STATE: NY
ZIP: 11598
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ProPhase Labs, Inc.
CENTRAL INDEX KEY: 0000868278
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 232577138
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 621 N. SHADY RETREAT ROAD
CITY: DOYLESTOWN
STATE: PA
ZIP: 18901
BUSINESS PHONE: 2153450919
MAIL ADDRESS:
STREET 1: 621 N. SHADY RETREAT ROAD
CITY: DOYLESTOWN
STATE: PA
ZIP: 18901
FORMER COMPANY:
FORMER CONFORMED NAME: QUIGLEY CORP
DATE OF NAME CHANGE: 19930328
4
1
form4.xml
X0306
4
2018-02-23
0
0000868278
ProPhase Labs, Inc.
PRPH
0001457896
Karkus Ted William
621 N. SHADY RETREAT ROAD
DOYLESTOWN
PA
18901
1
1
1
0
CEO & Chairman
Option (right to buy)
3.00
2018-02-23
4
A
0
2300000
0.00
A
2023-02-22
Common Stock
2300000
2300000
D
The transaction reported in this row involves a grant by the Issuer to the Reporting Person of options to purchase 2,300,000 shares of the Issuer's common stock that will vest and be exercisable in 35 equal monthly installments of 63,888 shares on the 1st day of each month beginning on March 1, 2018 (the "Initial Vesting Date"), and one monthly installment of 63,920 shares on the 1st day of the 36th month following the Initial Vesting Date, subject to Mr. Karkus' continued employment with the Company, and subject to accelerated vesting in the event Mr. Karkus' employment is terminated for any reason other than by the Company for cause or by Mr. Karkus without good reason. The stock option may not be exercised unless and until the requisite stockholder approval is attained.
/s/ Ted Karkus
2018-02-26